Disease · MONDO_0008487
Comparisons in its trials45
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 45
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm A: Clomiphene Citrate vs Arm B: Letrozole: Live Birth | 72 of 376 | 103 of 374 | 750 | NCT00719186 | Trial comparisons |
| Arm A: Clomiphene Citrate vs Arm B: Letrozole: Number of Pregnancy | 103 of 376 | 154 of 374 | 750 | NCT00719186 | Trial comparisons |
| Arm A: Clomiphene Citrate vs Arm B: Letrozole: serious adverse events | 13 of 376 | 21 of 374 | 750 | NCT00719186 | Trial comparisons |
| Day 1 Protocol vs Day 7 Protocol: serious adverse events | 2 of 65 | 4 of 65 | 130 | NCT01185704 | Trial comparisons |
| Metformin vs Placebo: serious adverse events | 0 of 55 | 0 of 59 | 114 | NCT00151411 | Trial comparisons |
| Arm 1:Letrozole-pioglitazone -Metformin Group vs Arm 2: Clomiphene Citrate-pioglitazone-metformin: Pregnancy Rate | 28 of 50 | 24 of 50 | 100 | NCT01909141 | Trial comparisons |
| Arm 1:Letrozole-pioglitazone -Metformin Group vs Arm 2: Clomiphene Citrate-pioglitazone-metformin: serious adverse events | 0 of 50 | 0 of 50 | 100 | NCT01909141 | Trial comparisons |
| Clomiphene Citrate vs Raloxifene: serious adverse events | 0 of 40 | 0 of 42 | 82 | NCT00427700 | Trial comparisons |
| Liraglutide Pen Injector (Saxenda) vs Placebo Liraglutide Pen Injector: deaths from any cause | 0 of 55 | 0 of 27 | 82 | NCT03480022 | Trial comparisons |
| Liraglutide Pen Injector (Saxenda) vs Placebo Liraglutide Pen Injector: serious adverse events | 0 of 55 | 0 of 27 | 82 | NCT03480022 | Trial comparisons |
| Liraglutide Pen Injector (Saxenda) vs Placebo Liraglutide Pen Injector: 5% Weight Loss From Baseline | 25 of 44 | 5 of 23 | 67 | NCT03480022 | Trial comparisons |
| Liraglutide Pen Injector (Saxenda) vs Placebo Liraglutide Pen Injector: 10% Body Weight Loss From Baseline | 13 of 44 | 2 of 23 | 67 | NCT03480022 | Trial comparisons |
| Vitamin D3 (Biodal 50,000IU) vs Placebo: serious adverse events | 0 of 30 | 0 of 30 | 60 | NCT02328404 | Trial comparisons |
| Tung's Acupuncture Group vs CPA/EE Group: deaths from any cause | 0 of 30 | 0 of 30 | 60 | NCT02729545 | Trial comparisons |
| Tung's Acupuncture Group vs CPA/EE Group: serious adverse events | 0 of 30 | 0 of 30 | 60 | NCT02729545 | Trial comparisons |
| MLE4901 Treatment Arm vs Placebo Treatment Arm: deaths from any cause | 0 of 30 | 0 of 25 | 55 | NCT02865915 | Trial comparisons |
| MLE4901 Treatment Arm vs Placebo Treatment Arm: serious adverse events | 1 of 30 | 0 of 25 | 55 | NCT02865915 | Trial comparisons |
| Diet Intervention vs GLP-1 Intervention: deaths from any cause | 0 of 17 | 0 of 38 | 55 | NCT03919929 | Trial comparisons |
| Diet Intervention vs GLP-1 Intervention: serious adverse events | 0 of 17 | 0 of 38 | 55 | NCT03919929 | Trial comparisons |
| 1/Pioglitazone vs 2/Placebo: serious adverse events | 0 of 26 | 0 of 25 | 51 | NCT00868140 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0008487/comparisons